STERIS

  • Backlog$409.5 MQ2, 2022
  • Revenue$3.1 BFY, 2021
  • Market Capitalization$20.8 B2022-06-29

OverviewSuggest Edit

STERIS is a provider of infection prevention and other procedural products and services. The company primarily develops, manufactures, sells, and distributes detergents, gastrointestinal endoscopy accessories, and barrier product solutions. Its products and services also include equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, as well as capital equipment products and connectivity solutions.

TypePublic
Founded1985
HQMentor, OH, USMap
Websitesteris.com
Employee Ratings3.8
Overall CultureCMore
View Jobs (973)

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2021)13,000
Job Openings973
Revenue (FY, 2021)$3.1 B(+3%)
Share Price (Jun 2022)$208.3(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at STERIS

Dan Carestio

Dan Carestio

President and CEO
Karen Burton

Karen Burton

Vice President, Controller and Chief Accounting Officer
Michael Tokich

Michael Tokich

Senior Vice President and Chief Financial Officer
Mary Clare Fraser

Mary Clare Fraser

Vice President and Chief Human Resources Officer
Show more

STERIS Office Locations

STERIS has offices in Mentor, , Birmingham, Chesterfield and in 53 other locations
Mentor, OH, US (HQ)
5960 Heisley Rd
Birmingham, AL, US
3316 2nd Ave N
Chesterfield, MO, US
515 Trade Center Blvd
Cooper City, FL, US
12229 SW 53rd St
Keller, TX, US
1077 Chisolm Trail
Libertyville, IL, US
1880 Industrial Dr
Show all (64)

STERIS Financials and Metrics

STERIS Revenue

Embed Graph
View revenue for all periods
STERIS's revenue was reported to be $3.11 b in FY, 2021 which is a 2.5% increase from the previous period.
USD

Revenue (Q2, 2022)

1.2b

Gross profit (Q2, 2022)

480.3m

Gross profit margin (Q2, 2022), %

40.1%

Net income (Q2, 2022)

69.6m

EBIT (Q2, 2022)

116.5m

Market capitalization (29-Jun-2022)

20.8b

Closing stock price (29-Jun-2022)

208.3

Cash (30-Sept-2021)

383.5m

EV

24.1b
STERIS's current market capitalization is $20.8 b.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

2.8b3.0b3.1b

Revenue growth, %

9%3%

Cost of goods sold

1.6b1.7b1.8b

Gross profit

1.2b1.3b1.3b
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022

Revenue

696.2m696.8m736.8m774.3m668.9m756.1m808.9m968.4m1.2b

Cost of goods sold

409.2m391.0m418.2m442.9m383.4m426.1m463.1m542.1m716.6m

Gross profit

287.0m305.8m318.7m331.4m285.6m330.0m345.9m426.3m480.3m

Gross profit Margin, %

41%44%43%43%43%44%43%44%40%
show all
Annual
USDFY, 2019FY, 2020FY, 2021

Cash

220.6m319.6m220.5m

Accounts Receivable

564.8m586.5m609.4m

Prepaid Expenses

60.0m54.4m66.8m

Inventories

208.2m248.3m315.1m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022

Cash

224.9m238.1m225.6m199.2m255.6m312.0m252.5m534.8m383.5m

Accounts Receivable

509.9m509.7m513.4m544.4m503.2m503.7m556.1m743.4m762.0m

Prepaid Expenses

58.1m63.0m56.2m57.2m61.4m56.0m73.3m136.6m194.6m

Inventories

227.6m233.6m236.8m252.0m277.0m278.6m294.1m593.1m564.5m
show all
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

305.1m407.8m396.9m

Depreciation and Amortization

225.9m197.2m219.2m

Inventories

(14.6m)(39.1m)3.8m

Accounts Payable

21.2m(2.8m)(7.2m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022

Net Income

196.2m84.8m179.9m284.6m88.1m194.1m308.7m(21.9m)47.7m

Depreciation and Amortization

175.7m47.1m96.7m146.3m49.0m103.4m160.2m83.6m201.7m

Inventories

(32.1m)(24.6m)(26.3m)(32.8m)(27.0m)(25.3m)(7.5m)(1.7m)(57.9m)

Accounts Payable

5.1m(17.3m)(19.1m)(18.6m)(17.0m)(27.5m)(31.0m)(4.6m)(260.0k)
show all
USDQ3, 2019

Revenue/Employee

58.0k

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

1.6 x
Show all financial metrics

STERIS Operating Metrics

STERIS's Backlog was reported to be $409.5m in Q2, 2022.
FY, 2016Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020FY, 2020Q1, 2021Q2, 2021Q3, 2021FY, 2021Q1, 2022Q2, 2022

Backlog

$278.1 m$215.2 m$246.1 m$269 m$281.5 m$242.5 m$231.9 m$252.8 m$297.5 m$286.2 m$346.4 m$409.5 m

Countries

100100100

Patents (US)

390400410450

Patents Pending

470

STERIS Acquisitions / Subsidiaries

Company NameDateDeal Size
Cantel Medical LLCJune 02, 2021$4.6 b
Key SurgicalNovember 18, 2020$853.2 m
Phoenix Surgical Holdings LtdAugust 31, 2016$14.3 m
Medisafe Holdings LtdJuly 22, 2016$34.5 m
Synergy Health plcNovember 02, 2015$2.3 b
Dana Products, Inc.March 09, 2015$12 k
AGAPE Instruments Service, Inc.December 31, 2014$3.42 k
Integrated Medical Systems International IncMay 09, 2014$162.91 k
Eschmann Holdings Ltd.February 10, 2014$25 m
Life Systems, Inc.February 04, 2014$24.5 k
Show more

STERIS Revenue Breakdown

Embed Graph

STERIS revenue breakdown by business segment: 23.1% from Capital equipment, 23.4% from Consumable and 53.5% from Service

STERIS revenue breakdown by geographic segment: 71.7% from United States, 26.0% from Other Foreign Countries and 2.3% from Other

STERIS Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

Learn more about our premium products
SecurityScorecard logo

STERIS Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

STERIS Online and Social Media Presence

STERIS's Trends

Embed Graph

STERIS Company Culture

  • Overall Culture

    C

    66/100

  • CEO Rating

    C-

    64/100

  • Compensation

    B-

    69/100

  • Diversity

    A

    81/100

Learn more on Comparably

STERIS News and Updates

May 11, 2022

STERIS Announces Financial Results for Fiscal 2022 Fourth Quarter and Full Year

DUBLIN, IRELAND, May 11, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 fourth quarter ended March 31, 2022. Revenue as reported for the quarter increased 39% to $1.2 billion compared with $873.5 million in the fou…
April 08, 2022

Global Disinfectant and Decontamination Markets, 2020-2021 & 2022-2026 - Key Players are STERIS, Ecolab, The Clorox Company, and Stepan Company

Dublin, April 08, 2022 (GLOBE NEWSWIRE) -- The "Global Disinfectant and Decontamination Market: Analysis By Product (Medical Devices Disinfectants, Enzymatic Cleaners, and Surface Disinfectants), By Region (NA, Europe, APAC and ROW) Size and Trends with Impact of COVID-19 and Forecast up to 2026" …
May 18, 2021

STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year

DUBLIN, IRELAND, May 18, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 fourth quarter ended March 31, 2021. Revenue as reported for the quarter increased 6% to $873.5 million compared with $823.0 million in the fou…
May 11, 2021

STERIS Announces Changes to Board of Directors

DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effect…
April 27, 2021

STERIS Announces Preliminary Financial Results for Fiscal 2021

DUBLIN, IRELAND, April 27, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced preliminary financial results for its fiscal 2021 year ending March 31, 2021. The Company expects to report that revenue as reported for fiscal 2021 increased approximately 3% to …
February 03, 2021

STERIS Announces Leadership Succession Plan

DUBLIN, IRELAND, Feb. 03, 2021 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that Walt Rosebrough, President and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the company’s Annual General Meeting. Mr. Rosebrough will r…
Show more

 STERIS Frequently Asked Questions

  • When was STERIS founded?

    STERIS was founded in 1985.

  • Who are STERIS key executives?

    STERIS's key executives are Dan Carestio, Karen Burton and Michael Tokich.

  • How many employees does STERIS have?

    STERIS has 13,000 employees.

  • What is STERIS revenue?

    Latest STERIS annual revenue is $3.1 b.

  • What is STERIS revenue per employee?

    Latest STERIS revenue per employee is $239 k.

  • Who are STERIS competitors?

    Competitors of STERIS include Getinge, Berendsen and Cantel Medical.

  • Where is STERIS headquarters?

    STERIS headquarters is located at 5960 Heisley Rd, Mentor.

  • Where are STERIS offices?

    STERIS has offices in Mentor, , Birmingham, Chesterfield and in 53 other locations.

  • How many offices does STERIS have?

    STERIS has 64 offices.